Antigen-delivery through invariant chain (CD74) boosts CD8 and CD4 T cell immunity

Area of Science:

• Immunology
• Cancer Research
• Vaccinology

Background:

• T-cell activation is crucial for tumor eradication and immune memory.
• While CD8 T-cells are a focus, CD4 helper T-cells are vital for vaccine efficacy.
• The invariant chain (Ii) is essential for MHC class II peptide loading and surface expression on antigen-presenting cells (APCs).

Purpose of the Study:

• To investigate if longer cancer peptides, replacing the CLIP region of Ii, can be loaded onto both MHC class I and II.
• To assess the potential of these modified Ii constructs as a cancer vaccine vector.

Main Methods:

• Replacing the CLIP peptide of the invariant chain (Ii) with longer cancer peptides.
• Utilizing antigen-presenting cells (APCs) to present peptides on both MHC class I and II.
• Comparing Ii-loading antigen presentation with an ER-targeted minigene construct.
• Priming CD4+ and CD8+ T cells from a naive population using Ii-expressing dendritic cells.

Main Results:

• Expanding the CLIP replacement size in Ii leads to T-cell activation.
• APCs successfully presented peptides from the same Ii molecule on both MHC class I and II.
• Ii-loading demonstrated superior antigen presentation compared to ER-targeted minigene constructs.
• Ii-expressing dendritic cells effectively primed naive CD4+ and CD8+ T cells.

Conclusions:

• Modified Ii constructs with expanded CLIP replacement can load and present cancer peptides on both MHC class I and II.
• This approach shows promise for developing effective cancer vaccines that elicit a robust, two-dimensional T-cell response.
• The findings suggest a novel strategy for enhancing cancer immunotherapy by optimizing antigen presentation pathways.